Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

April 30, 2024

https://www.globenewswire.com/news-release/2024/04/30/2872221/0/en/Senti-Bio-Announces-Publication-of-SENTI-202-Preclinical-Data-Demonstrating-Potential-of-Logic-Gated-CAR-NK-Cell-Therapy-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML.html

– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML –

– Data supports the design of Phase 1 clinical trial of SENTI-202 with patient dosing anticipated in the second quarter of 2024 –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.